Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.409 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=CC=CC=C2\C=C3/SCCN(C3=O)C4=CC(Cl)=C(Cl)C=C4
InChI
InChIKey=LHYMPSWMHXUWSK-STZFKDTASA-N
InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.409 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
CNS Activity
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:16 GMT 2023
by
admin
on
Fri Dec 15 15:35:16 GMT 2023
|
Record UNII |
933PJL964R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7047277
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
933PJL964R
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
205683-28-9
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
6914152
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
C556408
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110932
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
C72755
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
361343-19-3
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
8240
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY | |||
|
300000036934
Created by
admin on Fri Dec 15 15:35:16 GMT 2023 , Edited by admin on Fri Dec 15 15:35:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET->ANTAGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
EXCRETED UNCHANGED |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
M6 accounted (average of six human subjects) for 5.6% (sum of M5 and M6) of the administered dose in feces
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
sum of M5 and M6 counted for 5.6% of the administered dose in feces
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||